Propel Bio Management, LLC Fulcrum Therapeutics, Inc. Transaction History
Propel Bio Management, LLC
- $154 Billion
- Q2 2024
A detailed history of Propel Bio Management, LLC transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Propel Bio Management, LLC holds 750,000 shares of FULC stock, worth $6.47 Million. This represents 3.02% of its overall portfolio holdings.
Number of Shares
750,000
Previous 750,000
-0.0%
Holding current value
$6.47 Million
Previous $7.08 Billion
34.32%
% of portfolio
3.02%
Previous 4.12%
Shares
1 transactions
Others Institutions Holding FULC
# of Institutions
135Shares Held
59.5MCall Options Held
4.32MPut Options Held
307K-
Ra Capital Management, L.P. Boston, MA11.6MShares$100 Million1.08% of portfolio
-
Rtw Investments, LP New York, NY5.85MShares$50.5 Million0.61% of portfolio
-
Black Rock Inc. New York, NY4.8MShares$41.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.07MShares$26.5 Million0.0% of portfolio
-
Cowen And Company, LLC2.96MShares$25.6 Million0.47% of portfolio
About Fulcrum Therapeutics, Inc.
- Ticker FULC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,038,900
- Market Cap $449M
- Description
- Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...